FGFR3 Has Tumor Suppressor Properties in Cells with Epithelial Phenotype

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2013 Aug 2

PMID 23902722

Citations 22

Authors

Marie Lafitte

Isabelle Moranvillier

Stephane Garcia

Evelyne Peuchant

Juan Iovanna

Benoit Rousseau

Pierre Dubus

Veronique Guyonnet-Duperat

Genevieve Belleannee

Jeanne Ramos

Aurelie Bedel

Hubert de Verneuil

Francois Moreau-Gaudry

Sandrine Dabernat

Affiliations

Soon will be listed here.

Abstract

Background: Due to frequent mutations in certain cancers, FGFR3 gene is considered as an oncogene. However, in some normal tissues, FGFR3 can limit cell growth and promote cell differentiation. Thus, FGFR3 action appears paradoxical.

Results: FGFR3 expression was forced in pancreatic cell lines. The receptor exerted dual effects: it suppressed tumor growth in pancreatic epithelial-like cells and had oncogenic properties in pancreatic mesenchymal-like cells. Distinct exclusive pathways were activated, STATs in epithelial-like cells and MAP Kinases in mesenchymal-like cells. Both FGFR3 splice variants had similar effects and used the same intracellular signaling. In human pancreatic carcinoma tissues, levels of FGFR3 dropped in tumors.

Conclusion: In tumors from epithelial origin, FGFR3 signal can limit tumor growth, explaining why the 4p16.3 locus bearing FGFR3 is frequently lost and why activating mutations of FGFR3 in benign or low grade tumors of epithelial origin are associated with good prognosis. The new hypothesis that FGFR3 can harbor both tumor suppressive and oncogenic properties is crucial in the context of targeted therapies involving specific tyrosine kinase inhibitors (TKIs). TKIs against FGFR3 might result in adverse effects if used in the wrong cell context.

Citing Articles

GPNMB is a novel binding partner of FGFR1 that affects tumorigenic potential through AKT phosphorylation in TNBC.

Elhinnawi M, Okita Y, Shigematsu K, Abdelaziz M, Shiratani R, Kawanishi K Cancer Sci. 2024; 116(2):432-443.

PMID: 39609108 PMC: 11786315. DOI: 10.1111/cas.16419.

Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules.

Chen L, Singha Roy S, Jadhav A, Wang W, Chen P, Bishop T ACS Chem Biol. 2024; 19(9):1918-1929.

PMID: 39250704 PMC: 11421428. DOI: 10.1021/acschembio.4c00438.

Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression-A Scoping Review.

Orlandi E, Guasconi M, Vecchia S, Trubini S, Giuffrida M, Proietto M Cancers (Basel). 2024; 16(16).

PMID: 39199681 PMC: 11352631. DOI: 10.3390/cancers16162912.

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.

Noeraparast M, Krajina K, Pichler R, Niedersuss-Beke D, Shariat S, Grunwald V Cancer Commun (Lond). 2024; 44(10):1189-1208.

PMID: 39161208 PMC: 11483561. DOI: 10.1002/cac2.12602.

Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.

Lin Q, Serratore A, Niu J, Shen S, Roy Chaudhuri T, Ma W Drug Resist Updat. 2024; 73:101064.

PMID: 38387284 PMC: 11864563. DOI: 10.1016/j.drup.2024.101064.

References

Leung H, Gullick W, Lemoine N . Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994; 59(5):667-75. DOI: 10.1002/ijc.2910590515. View

Bellido T, OBrien C, Roberson P, Manolagas S . Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem. 1998; 273(33):21137-44. DOI: 10.1074/jbc.273.33.21137. View

Sibley K, Cuthbert-Heavens D, Knowles M . Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 2001; 20(6):686-91. DOI: 10.1038/sj.onc.1204110. View

Lafitte M, Rousseau B, Moranvillier I, Taillepierre M, Peuchant E, Guyonnet-Duperat V . In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. Mol Cancer. 2012; 11:81. PMC: 3546072. DOI: 10.1186/1476-4598-11-81. View

McInroy L, Maatta A . Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun. 2007; 360(1):109-14. DOI: 10.1016/j.bbrc.2007.06.036. View

Hirotsu M, Setoguchi T, Matsunoshita Y, Sasaki H, Nagao H, Gao H . Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer. 2009; 101(12):2030-7. PMC: 2795447. DOI: 10.1038/sj.bjc.6605407. View

Ronchetti D, Greco A, Compasso S, Colombo G, DellEra P, Otsuki T . Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene. 2001; 20(27):3553-62. DOI: 10.1038/sj.onc.1204465. View

Li Z, Zhu Y, Plowright E, Bergsagel P, Chesi M, Patterson B . The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood. 2001; 97(8):2413-9. DOI: 10.1182/blood.v97.8.2413. View

Cappellen D, de Oliveira C, Ricol D, de Medina S, BOURDIN J, Sastre-Garau X . Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23(1):18-20. DOI: 10.1038/12615. View

10.

Bernard-Pierrot I, Brams A, Dunois-Larde C, Caillault A, Gil Diez de Medina S, Cappellen D . Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 2005; 27(4):740-7. DOI: 10.1093/carcin/bgi290. View

11.

Colvin J, Bohne B, Harding G, McEwen D, Ornitz D . Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet. 1996; 12(4):390-7. DOI: 10.1038/ng0496-390. View

12.

Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-29. DOI: 10.1038/nrc2780. View

13.

Efrat S, Lemberg H, Al Emran O, Wang X . Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci U S A. 1995; 92(8):3576-80. PMC: 42210. DOI: 10.1073/pnas.92.8.3576. View

14.

Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P . Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle. 2010; 9(15):3085-99. DOI: 10.4161/cc.9.15.12521. View

15.

Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A . Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006; 24(22):3664-71. DOI: 10.1200/JCO.2005.05.1771. View

16.

Li C, Chen L, Iwata T, Kitagawa M, Fu X, Deng C . A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet. 1999; 8(1):35-44. DOI: 10.1093/hmg/8.1.35. View

17.

Dai H, Holm R, Kristensen G, Abeler V, Borresen-Dale A, Helland A . Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas. Anal Cell Pathol. 2002; 23(2):45-9. PMC: 4618581. DOI: 10.1155/2001/521873. View

18.

Roger L, Jullien L, Gire V, Roux P . Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci. 2010; 123(Pt 8):1295-305. DOI: 10.1242/jcs.061002. View

19.

LHote C, Knowles M . Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res. 2005; 304(2):417-31. DOI: 10.1016/j.yexcr.2004.11.012. View

20.

Mhawech-Fauceglia P, Cheney R, Fischer G, Beck A, Herrmann F . FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol. 2006; 32(2):231-7. DOI: 10.1016/j.ejso.2005.11.018. View